Related Experiment Video
Updated: Jun 25, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Individualising Antithrombotic Strategies for Acute and Chronic Coronary Syndromes
1Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield Sheffield, UK.
Insights
Current guidelines for acute coronary syndromes emphasize balancing ischemic event and bleeding risks with antithrombotic therapy. High bleeding risk patients require careful consideration of treatment duration and intensity.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Current guidelines offer various antithrombotic treatment options for acute and chronic coronary syndromes.
- The European Society of Cardiology 2023 guidelines highlight the importance of assessing both ischemic and bleeding risks.
Purpose of the Study:
- To illustrate the application of current guidelines and expert consensus on antithrombotic therapy in clinical practice.
- To provide practical examples for managing antithrombotic treatment in patients with coronary syndromes.
Main Methods:
- Review of European Society of Cardiology 2023 guidelines for acute coronary syndrome management.
- Incorporation of a joint expert consensus informed by network meta-analyses and individual participant data.
- Analysis of four distinct clinical case studies.
Main Results:
- Guidelines and consensus recommend individualized antithrombotic strategies based on ischemic and bleeding risk assessment.
- Particular attention is needed for high bleeding risk patients regarding therapy duration and intensity.
- Case studies demonstrate practical application of these recommendations.
Conclusions:
- Clinical practice should integrate guideline recommendations and expert consensus for optimal antithrombotic therapy.
- Risk stratification is crucial for tailoring antithrombotic treatment in coronary syndromes.
- Case studies serve as valuable learning tools for healthcare professionals.
Abstract:
For patients presenting with acute or chronic coronary syndromes, current guideline recommendations and expert consensus provide a range of options for antithrombotic treatment. The European Society of Cardiology 2023 guidelines on the management of acute coronary syndrome emphasise the need to assess the risk of both ischaemic events and bleeding. Those with high bleeding risk warrant particular consideration of the duration and intensity of antithrombotic therapy combinations. A joint consensus of experts takes a similar approach, informed by two network meta-analyses that appraised all available antithrombotic treatments within or after the 12 months following coronary revascularisation and/or acute coronary syndrome and individual participant data from six trials. In this article, four case studies are used to illustrate how these guidelines and expert consensus recommendations can be applied in clinical practice.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Cardiovascular Drugs: Classification based on Therapeutic Indications

